Compare · HIMS vs WGS
HIMS vs WGS
Side-by-side comparison of Hims & Hers Health Inc. (HIMS) and GeneDx Holdings Corp. (WGS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HIMS and WGS operate in Medical/Nursing Services (Health Care), so they compete in similar markets.
- HIMS is the larger of the two at $6.06B, about 3.3x WGS ($1.86B).
- WGS has been more active in the news (5 items in the past 4 weeks vs 4 for HIMS).
- HIMS has more recent analyst coverage (25 ratings vs 8 for WGS).
- Company
- Hims & Hers Health Inc.
- GeneDx Holdings Corp.
- Price
- -
- -
- Market cap
- $6.06B
- $1.86B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Nursing Services
- Medical/Nursing Services
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- 2020
- News (4w)
- 4
- 5
- Recent ratings
- 25
- 8
Hims & Hers Health Inc.
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available for purchase on its websites directly by customers. It provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, as well as cosmetics and supplement products, primarily focusing on wellness, sexual health, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, collagen protein, biotin, and teas in the wellness category; moisturizer, fragrances, face wash, and anti-wrinkle creams in the skincare category; condoms and lubricants in the sexual health category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. It also offers medical consultation services; and engages in the wholesale of non-prescription product sales to retailers. Hims & Hers Health, Inc. is based in San Francisco, California.
Latest HIMS
- Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
- Hims & Hers Benefits Adds Grüns, Medjet, Tonal, and Viome for Whole-Body Health and Support When You Need It Most
- Chief Legal Officer Boughton Soleil sold $95,551 worth of shares (3,462 units at $27.60) as part of a pre-agreed trading plan (SEC Form 4)
- Hims Expands Testosterone Care with Injectable and Oral TRT, Its Largest Men’s Health Launch to Date
- Chief Legal Officer Boughton Soleil sold $100,577 worth of shares (3,461 units at $29.06) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 3 filed by Hims & Hers Health Inc.
- Hims & Hers to Announce Third Quarter 2026 Financial Results on November 9, 2026
- Hers Launches in Australia, Built to Care for the Whole Woman
- SEC Form 8-K filed by Hims & Hers Health Inc.
- Hims & Hers Names Jon Franklin as Chief Accounting Officer
Latest WGS
- SEC Form SCHEDULE 13G filed by GeneDx Holdings Corp.
- GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing
- GeneDx to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026
- GeneDx Expands Diagnostic Leadership with Long-Read Genome Sequencing, Advancing Rare Disease Diagnosis
- GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026
- GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026
- GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric Care
- CHIEF EXECUTIVE OFFICER Stueland Katherine converted options into 18,750 shares and sold $1,025,013 worth of shares (10,501 units at $97.61), increasing direct ownership by 8% to 115,476 units (SEC Form 4) (withholding obligation)
- CHIEF FINANCIAL OFFICER Feeley Kevin converted options into 7,197 shares and sold $363,892 worth of shares (3,728 units at $97.61), increasing direct ownership by 8% to 44,945 units (SEC Form 4) (tax withholding)
- Director Fuchs Thomas converted options into 1,146 shares (SEC Form 4)